Adverse Hematological and Non-Hematological Events in Patients With Relapsed/Refractory Multiple Myeloma That Are Responsive to Daratumumab, Pomalidomide and Dexamethasone.

Omar AlkharabshehPolina BellmanZahra MahmoudjafariWei CuiShebli AtrashBarry PaulHamza HashmiLeyla ShuneNausheen AhmedAl-Ola Abdallah

Published in: Journal of hematology (2023)

Our study revealed that patients who respond to DPd are at high risk of dose reduction or treatment interruption because of hematological toxicity, typically due to neutropenia and leukopenia leading to increased risk of hospitalization and pneumonia.

Keyphrases

multiple myeloma
oxidative stress
high dose
emergency department
acute myeloid leukemia
cancer therapy
acute lymphoblastic leukemia
drug delivery
replacement therapy
smoking cessation